CompletedNCT04864834
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
PHASE3 · 485 planned enrolment
- Countries listed
- 16
- Registry update
- March 26, 2024
